- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.12. | OnKure reports positive early trial data for cancer drug OKI-219 | 1 | Investing.com | ||
| 10.12. | OnKure meldet positive frühe Studiendaten für Krebsmedikament OKI-219 | 3 | Investing.com Deutsch | ||
| 10.12. | OnKure Therapeutics, Inc.: OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 | 48 | GlobeNewswire (Europe) | -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated... ► Artikel lesen | |
| 10.12. | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.12. | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 25.11. | OnKure Therapeutics, Inc.: OnKure Announces New Date for Upcoming Investor Call | 3 | GlobeNewswire (USA) | ||
| 07.11. | OnKure Therapeutics announces accounting firm change | 5 | Investing.com | ||
| 07.11. | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11. | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 01.11. | OnKure Therapeutics, Inc.: OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium | 2 | GlobeNewswire (USA) | ||
| 25.10. | vTv Therapeutics ends key license agreement with OnKure | 2 | Investing.com | ||
| 23.10. | OnKure files to sell 2.94M shares of Class A Common Stock for holders | 4 | Seeking Alpha | ||
| 10.10. | Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm | 1 | Benzinga.com | ||
| 10.10. | OnKure started at outperform by Oppenheimer, OKI-219 potential cited | 2 | Seeking Alpha | ||
| 10.10. | OnKure shares initiated with Outperform rating on drug potential | 2 | Investing.com | ||
| 08.10. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.10. | OnKure and Reneo Pharmaceuticals complete merger | 2 | Pharmaceutical Technology | ||
| 04.10. | OnKure Therapeutics, Inc. Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million | 171 | GlobeNewswire (Europe) | -- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Ka), initially in breast cancer -- On track to announce early clinical... ► Artikel lesen | |
| 03.10. | Reneo Pharmaceuticals stockholders approve merger with OnKure | 1 | Seeking Alpha | ||
| 03.10. | Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure | 161 | GlobeNewswire (Europe) | - Combined company to trade on Nasdaq under ticker "OKUR" - Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq:... ► Artikel lesen |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 25,300 | +0,06 % | Prognose für 2025 präsentiert: Pfizer: So billig ist die 6,7-Prozent-Dividende jetzt zu haben! | © Foto: Foto: Nicolas Maeterlinck/ - BELGA/dpaDer US-Pharmakonzern hat am Dienstagmittag seine Prognose für das kommende Geschäftsjahr vorgestellt. Diese liegt größtenteils im Rahmen der Erwartungen.Pfizer... ► Artikel lesen | |
| SANOFI | 91,28 | +0,10 % | Sanofi SA-Aktie legt um 1,25 Prozent zu (88,88 €) | Im Plus liegt aktuell das Wertpapier von Sanofi SA . Der jüngste Kurs betrug 88,88 Euro. Heute hat sich am Aktienmarkt die Aktie von Sanofi SA zwischenzeitlich um 1,25 Prozent verteuert. Der Kurs des... ► Artikel lesen | |
| INNOCAN PHARMA | 0,121 | 0,00 % | Innocan Pharma Corporation: Innocan Pharma Announces Private Placement of Units | HERZLIYA, Israel and CALGARY, AB, Dec. 19, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 14,600 | +0,34 % | Assembly Bio: Gilead erhöht Anteil vor Readouts! | Während viele Biotech-Titel zum Jahresende noch einmal starke Kursabstürze erfahren, hält sich mein Top-Favorit Assembly Biosciences (WKN: A402CB) auf Jahressicht weiter stark mit einer Performance... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 9,560 | +1,16 % | Astria Therapeutics, Inc. - 8-K, Current Report | ||
| NEKTAR THERAPEUTICS | 0,874 | -1,41 % | Nektar's NKTR-255 After CD19 CAR-T Therapy Enhances Complete Response In R/R Large B-Cell Lymphoma | WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) announced results of its Phase 2 proof-of-concept study, which evaluated NKTR-255 as an adjuvant treatment to enhance complete response rate... ► Artikel lesen | |
| ROCKET LAB USA | 23,900 | 0,00 % | Space Technology: Rocket Lab stellt zweites Raumfahrzeug für Varda Space Industries fertig | ||
| ALTIMMUNE | 8,240 | +3,97 % | Altimmune, Inc: Altimmune Added to Nasdaq Biotechnology Index | GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index... ► Artikel lesen | |
| ROYALTY PHARMA | 23,670 | -1,13 % | Royalty Pharma-Aktie erreicht 52-Wochen-Tief bei 24,7 US-Dollar | ||
| BRIDGEBIO PHARMA | 25,740 | +1,30 % | HC Wainwright Reiterates Buy Rating for BridgeBio Pharma (NASDAQ:BBIO) | ||
| SOLIGENIX | 2,980 | -3,25 % | SOLIGENIX, INC.: Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma | FLASH2 Study opens patient enrollment PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company... ► Artikel lesen | |
| KALA BIO | 5,685 | +4,03 % | KALA BIO, Inc. - 10-Q, Quarterly Report | ||
| BOIRON | 26,600 | -0,19 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 2,709 | +3,28 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WAYNE, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS)(the "Company" or "Aclaris"), a clinical-stage biopharmaceutical company focused on developing novel drug candidates... ► Artikel lesen | |
| NEUROGENE | 21,000 | -3,67 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 20.11.2024 | The following instruments on XETRA do have their first trading 20.11.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.11.2024
Aktien
1 PLRNBWT00031 Rainbow Tours S.A.
2... ► Artikel lesen |
Das Unternehmen ONKURE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,090 (+1,12 %) liegt der Kurs bei 8,160 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONKURE THERAPEUTICS INC finden Sie auf Wallstreet Online.
